Public Relations
Provista Diagnostics
PR@ProvistaDx.com
212-202-3170

Provista Diagnostics Accepted for a Late-Breaking Data Presentation at the 2014 San Antonio Breast Cancer Symposium

Data Explores the Ability of Serum Protein Biomarkers in Conjunction with Tumor Associated Autoantibodies to Distinguish Between Benign and Invasive Breast Lesions

New York, NY – November 10, 2014 – Provista Diagnostics, Inc., a privately-held molecular diagnostics company focused on developing and commercializing a new generation of proprietary blood-based diagnostic, prognostic and monitoring tests designed to address the unmet needs in women's cancer, such as breast and gynecologic cancers, today announced acceptance of a late-breaking poster presentation at the 2014 San Antonio Breast Cancer Symposium taking place December 9-13, 2014 in San Antonio, Texas.

The poster titled, "Provista-001: a multi-center prospective study of protein signature used in the differentiation of benign breast lesions from invasive breast cancer in women under the age of 50 with a BI-RADS® 3 or 4," will be presented in the Detection and Diagnosis Poster Session.

The American College of Radiology (ACR) utilizes a standard reporting system to describe mammogram findings and results called the Breast Imaging Reporting and Data System (BI-RADS®). This system defines assessment categories that are predictive of the likelihood of malignancy and the results are sorted into classifications numbered 0 through 6. BI-RADS® 3 and 4 lesions represent a key decision point for radiologists as to biopsy or reassess via imaging in six months.

The poster will highlight data from the Company's 001 randomized, blinded prospective trial consisting of 351 women under the age of 50 whose suspicious mammograms were scored as either BI-RADS® 3 or 4. The study enrolled volunteers at 8 sites across the US. These women were assessed with Provista's proprietary diagnostic test that is used in combination with standard imaging. The results will

demonstrate the ability of the combinatorial profile of Serum Protein Biomarkers (SPB), select patient data and Tumor Associated Autoantibodies (TAABs) to help differentiate benign from cancerous lesions in a prospective setting. The ultimate objective is a more precise identification of deadly breast cancers in women.

Provista Diagnostics is currently conducting multiple trials to establish the combined role of SPBs and TAAs to differentiate benign from invasive breast cancers in woman 25 to 75 years old.

"We are very excited to be accepted to present our late-breaking data at the 2014 San Antonio Breast Symposium, as it is one of the premier clinical and scientific meetings focused on breast cancer diagnosis and treatment," said David Reese, PhD, President and CEO of Provista.

According to the American Cancer Society, nearly 233,000 women will be diagnosed with breast cancer in the U.S. in 2014. Approximately 40,000 deaths occur from breast cancer each year. While biomarkers are often used to augment detection of various cancers, definitive biomarkers for breast cancer have remained elusive.

About Provista

Provista Diagnostics is a privately held molecular diagnostics company focused on developing and commercializing a new generation of proprietary blood-based proteomic diagnostic, prognostic and monitoring tests designed to address the unmet needs in women's cancer, such as breast and gynecologic cancers. Provista Diagnostics' state-of-the-art, high-complexity clinical laboratory is accredited by the College of American Pathologists (CAP) and with the Clinical Laboratory Improvement Amendments (CLIA).

Additional information about Provista Diagnostics is available at ProvistaDx.com
Information about Provista Diagnostics' clinical trials is available at ClinicalTrials.gov

Safe Harbor Statement

Statements contained in this communication not relating to historical facts are forward-looking statements that are intended to fall within the safe harbor rule for such statements under the Private Securities Litigation Reform Act of 1995. The information contained in the forward-looking statements is inherently uncertain, and Provista's actual results may differ materially due to a number of factors, many of which are beyond Provista's ability to predict or control, including among others, viability and

effectiveness of our sales approach and overall marketing strategies, the outcome of development or regulatory review of our products, commercial success or acceptance by the medical community, competitive responses, our ability to raise additional capital, and the ability to successfully file a registration statement with the SEC. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual events to differ from the forward-looking statements. Provista operates in a highly competitive and rapidly changing business and regulatory environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. Except as is expressly required by the federal securities laws, Provista undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason.

###